Base-promoted cascade recyclization of allomaltol derivatives containing an amide fragment into substituted 3-(1-hydroxyethylidene)tetronic acids

  1. ORCID Logo ,
  2. ORCID Logo and
  3. ORCID Logo
N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky Pr., 47, Moscow, 119991, Russian Federation
  1. Corresponding author email
Associate Editor: J. A. Murphy
Beilstein J. Org. Chem. 2024, 20, 2585–2591. https://doi.org/10.3762/bjoc.20.217
Received 02 Jul 2024, Accepted 27 Sep 2024, Published 14 Oct 2024
Full Research Paper
cc by logo

Abstract

For the first time, recyclization of allomaltol derivatives with an amide fragment in the side chain were investigated. It was shown that the studied process leads to substituted tetronic acids bearing a pyrrolidinone moiety. The application of 1,1′-carbonyldiimidazole and DBU is necessary for implementation of the considered reaction. Based on the performed research a general method for the synthesis of a wide range of (3E,5E)-3-(1-hydroxyethylidene)-5-(5-oxopyrrolidin-2-ylidene)furan-2,4(3H,5H)-diones was elaborated. The advantages of the presented protocol are easily available starting compounds and simple isolation of the target products without chromatographic purification. The synthetic utility of the prepared tetronic acids was demonstrated by further transformations at the hydroxyethylidene fragment. The structures of one obtained tetronic acid and one product of derivatization were confirmed by X-ray analysis.

Introduction

3-Hydroxypyran-4-one derivatives are an important class of heterocyclic compounds widely represented in various naturally occurring sources [1-4]. Products of this type demonstrate a broad range of biological activity [5-13]. For example, 2-hydroxymethyl-5-hydroxypyran-4-one (kojic acid) is a well-known skin whitening agent extensively used in the cosmetic, medicine and food industries. The action of this compound is based on inhibition of tyrosinase activity, which helps to protect against ultraviolet radiation [14-16]. It should be noted that kojic acid is easily produced from carbohydrate sources in multi-tonnage quantity. Another interesting representative of this class is allomaltol readily available from kojic acid. Due to significant accessibility of the aforementioned 3-hydroxypyran-4-ones these products are widely used in organic synthesis [17-23].

Among the diverse chemical transformations of allomaltol derivatives the recyclizations of the pyranone ring are of great interest. As a rule, such reactions are realized under action of nitrogen-containing nucleophiles and open access to a large array of substituted pyridin-4-ones. Various conditions and reagents employed for these transformations are presented in numerous papers [24-29]. Besides that, approaches to the synthesis of pyridazinones and pyrazoles based on the interaction of 3-hydroxypyran-4-ones with hydrazine are known [30,31]. At the same time all considered recyclizations proceed under action of additional components and the intramolecular variant of this reaction is not described in the literature. It can be supposed that in the case of a substrate containing an allomaltol unit and a nucleophilic fragment in the side chain various transformations are possible. For example, a pyranone ring can be opened and recyclized into the novel heterocyclic system. Indeed, previously we have shown that various allomaltols 1 containing a hydrazide moiety are converted into substituted 3-acetyltetronic acids 2 under action of 1,1-carbonyldiimidazole (CDI) [32] (Scheme 1A). We assumed that the aforementioned synthetic strategy can be extended to other 3-hydroxypyran-4-one derivatives with a nitrogen functional group in the side chain.

[1860-5397-20-217-i1]

Scheme 1: Synthesis of tetronic acid derivatives.

Ongoing our research in this area in the present communication we have studied the recyclization of amide-containing allomaltol derivatives 3 under action of CDI (Scheme 1B). In this case, the interaction also leads to substituted tetronic acids 4. Wherein, in contrast to related hydrazide derivatives 1 the considered process can be realized only in the presence of a strong base (DBU).

Results and Discussion

The starting allomaltols 3 bearing an amide fragment in the side chain were prepared by reaction of dihydropyranones 5 with appropriate amines 6 applying the previously described method [33,34] (Scheme 2).

[1860-5397-20-217-i2]

Scheme 2: Synthesis of amide derivatives 3.

At first, amide 3a was selected as a model object for the present investigation. Initially, we tried to realize the supposed recyclization under conditions suggested earlier for the similar hydrazide derivatives (3 equiv of CDI, MeCN, reflux, 0.5 h). In this case the starting compound 3a didn’t undergo any transformations and was isolated in unchanged form. It should be mentioned that the key step of the studied recyclization is an intramolecular nucleophilic addition of a nitrogen atom at the double bond of the pyranone ring. Comparing the chemical properties of the considered amides and hydrazides it can be assumed that the nucleophilic activity of the amide nitrogen atom is insufficient for this transformation. In this regard, we hypothesized that application of basic reagent can facilitate this process by generating an anion from the amide moiety. For this purpose, we tested the investigated process using various bases under conditions described earlier for corresponding hydrazides. So, among the employed basic agents (Et3N, DABCO, DBU, DMAP, K2CO3, AcONa) only in the case of DBU the expected recyclization was observed and the target product 4a was obtained in 15% yield. In order to enhance the yield of compound 4a we tried to perform this reaction using DBU under various conditions and the results are presented in Table 1.

Table 1: Optimization of the reaction conditionsa.

[Graphic 1]
Entry Solvent Temperature Time, h Yield, %
1 MeCN reflux 0.5 15
2 MeCN reflux 3 22
4 MeCN reflux 6 18
5 MeCN rt 3 13
6 MeCN rt 12 44
7 MeCN rt 24 62
8 MeCN rt 48 61
9 dioxane rt 24 54
10 toluene rt 24 49
11 CH2Cl2 rt 24 51

aReaction conditions: 3a (0.37 g, 1 mmol), CDI (0.49 g, 3 mmol), DBU (0.17 g, 1.1 mmol), solvent (7 mL).

At first, we increased the time of reflux from 0.5 h to 3 h (Table 1, entry 2). As a result, a slight improvement of the yield of product 4a was achieved. Note that the further elongation of the process time led to decrease of the yield due to partial tarring of the reaction mixture (Table 1, entry 3). Next, we assumed that the investigated reaction can be performed at room temperature. However, stirring under these conditions for 3 h in MeCN didn’t enhance the yield of compound 4a (Table 1, entry 4). Nevertheless, in this case the increase in process time allowed us to significantly improve the yield of tetronic acid 4a (Table 1, entry 5). Wherein, the optimal time of the studied recyclization was 24 h (Table 1, entry 6) and further prolongation didn’t influence on the yield (Table 1, entry 7). Then, we tested the investigated reaction in various solvents at room temperature for 24 h. It should be noted that all solvents used had no advantage over MeCN (Table 1, entries 8–11). Thus, the best results for considered recyclization were achieved at stirring of amide 4a in the presence of CDI and DBU in MeCN at room temperature for 24 h.

The aforementioned optimal conditions were utilized for the synthesis of a wide range of tetronic acids bearing a pyrrolidinone unit (Scheme 3). The presented protocol is of general nature and allows us to prepare the final products with various aliphatic substituents at the ring nitrogen atom. Besides that, we managed to perform the investigated reaction using the corresponding aniline derivative 4r. It should be mentioned that in this case the considered recyclization proceeded in lower yield comparing with other amides and was accompanied by formation of various unidentified byproducts.

[1860-5397-20-217-i3]

Scheme 3: Synthesis of target tetronic acids 4a. aReaction conditions: 3a (1 mmol), CDI (0.49 g, 3 mmol), DBU (0.17 g, 1.1 mmol), MeCN (7 mL).

The obtained tetronic acids 4 are solid crystalline compounds, whose structure was proved by 1H, 13C NMR spectroscopy and high-resolution mass spectrometry. The 1H NMR spectra of the synthesized products contain characteristic signals of protons of the methyl fragment in the region δ = 2.5–2.4 ppm and methylene unit at δ = 2.7–2.5 ppm. The remaining signals are also in good agreement with the presented structure. Besides that, compound 4 has been analyzed using X-ray diffraction (Figure 1). It is important to emphasize that based on X-ray data the structure of synthesized products is different from previously described 3-acetyltetronic acids 2 obtained from the corresponding hydrazides 1. As well as in the case of compounds 2 for the amide derivatives 4 the double bond between pyrrolidinone and furanone parts has E-configuration. Only for sterically hindered compound 4t with a cyclohexylamine moiety the final product contains 20% of Z-isomer. At the same time, the considered products are differed by disposition of double and hydrogen bonds in the tetronic acid moiety. So, in the case of hydrazide derivatives the additional nitrogen atom participates in the formation of an intramolecular hydrogen bond and the double bond is located in the furanone ring. In contrast to the aforementioned example the considered compounds 4 have an exocyclic enol fragment and the intramolecular hydrogen bond is connected to the carbonyl oxygen atom. Thus, the absence of additional nitrogen atoms in compounds 4 leads to the fact that the other tautomeric form becomes more favorable.

[1860-5397-20-217-1]

Figure 1: The X-ray crystal structure of compound 4a (CCDC 2352876).

A proposed mechanism of the investigated recyclization is presented in Scheme 4. Initially, imidazolide A is formed via condensation of the starting amide 3 with CDI. Then, intermediate A deprotonates to the anion B under action of DBU. Subsequent intramolecular cyclization at the double bond of pyranone fragment leads to the formation of spiro compound C. Next, opening of the dihydropyranone ring results in pyrrolidin-2-one D which further transformed to the salt of 3-acyltetronic acid E. Finally, neutralization of intermediate E by HClconc leads to target product 4.

[1860-5397-20-217-i4]

Scheme 4: Proposed reaction mechanism for the formation of products 4.

It is interesting to note that chemical properties of the synthesized furanones differ from previously described 3-acetyltetronic acids 2 obtained from the corresponding hydrazides 1. As it was shown in a prior paper compounds 2 are easily deacetylated under reflux in MeOH for 8 h. At the same time the compounds 4 described in the present communication are more stable and under these conditions the loss of the acetyl group was not observed. It can be supposed that described above difference in configuration of the enol fragments and hydrogen bonds leads to the alteration in chemical behavior. Based on the aforementioned stability of tetronic acids 4 toward action of MeOH we supposed that various derivatives at the hydroxyethylidene group can be synthesized. For example, interaction of compound 4a with hydrazine in refluxing EtOH allowed us to obtain substituted enehydrazine 7 (Scheme 5a). The similar condensation with amine 8 led to enamine derivative 9 (Scheme 5b). Based on the data of X-ray analysis compound 7 has the same configuration of double and hydrogen bonds as in the case of starting tetronic acids 4 (Figure 2).

[1860-5397-20-217-i5]

Scheme 5: Synthesis of derivatization products 7 and 9.

[1860-5397-20-217-2]

Figure 2: The X-ray crystal structure of compound 7 (CCDC 2352878).

Conclusion

In summary, we have investigated the recyclization of allomaltol derivatives with an amide fragment in the side chain. It was shown that 3-(1-hydroxyethylidene)tetronic acid derivatives containing a pyrrolidinone moiety are formed as a result of the studied reaction. The considered process was performed in the presence of 1,1′-carbonyldiimidazole and DBU using MeCN as a solvent. The set of various (3E,5E)-3-(1-hydroxyethylidene)-5-(5-oxopyrrolidin-2-ylidene)furan-2,4(3H,5H)-diones was synthesized employing the developed approach. The readily accessible starting materials and simple purification procedure are the advantages of the considered method. The synthetic utility of obtained tetronic acids was demonstrated by preparation of enamine and enehydrazine derivatives. The structures of one target tetronic acid and synthesized enehydrazine were established by X-ray analysis.

Experimental

Unless otherwise stated, all starting chemicals were commercially available and were used as received. The starting compounds 1 were prepared by a procedure described in the literature [33,34]. NMR spectra were recorded with Bruker AM 300 (300 MHz) in DMSO-d6. Chemical shifts (ppm) are given relative to solvent signals (DMSO-d6: 2.50 ppm (1H NMR) and 39.52 ppm (13C NMR)). High-resolution mass spectra (HRMS) were obtained on a Bruker micrOTOF II instrument using electrospray ionization (ESI). The melting points were determined on a Kofler hot stage apparatus. A magnetic stirrer IKA C-MAG HS 7 was used for the reactions that require heating.

General experimental procedure for the synthesis of tetronic acids 4

A mixture of corresponding amide 3 (1 mmol) and 1,1-carbonyldiimidazole (0.49 g, 3 mmol) was stirred in acetonitrile (7 ml) for 5 min at room temperature, then DBU (0.17 g, 1.1 mmol) was added and resulting solution was kept overnight. After complete the conversion H2O (50 mL) and HClconc (0.7 g) were added to reaction mixture. The precipitated product was filtered off and washed with H2O (3 × 5 mL) and Et2O (3 × 5 mL).

(3E,5E)-3-(1-Hydroxyethylidene)-5-(3-oxo-2-phenethyl-2-azaspiro[4.5]decan-1-ylidene)furan-2,4(3H,5H)-dione (4a). Pale yellow powder; yield 62% (0.25 g); mp 121–123 °C; 1H NMR (300 MHz, DMSO-d6) δ 7.31–7.13 (m, 5H), 4.34 (t, J = 7.5 Hz, 2H), 2.74 (t, J = 7.6 Hz, 2H), 2.56–2.48 (m, 2H in DMSO), 2.46 (s, 3H), 2.14 (t, J = 11.8 Hz, 2H), 1.64–1.54 (m, 3H), 1.41–1.09 (m, 5H); 13C NMR (75 MHz, DMSO-d6) δ 178.2, 175.5, 164.8, 138.1, 128.9, 128.3, 126.4, 98.7, 44.3, 44.0, 39.4, 32.6, 32.1, 24.7, 23.9, 21.9; HRMS (ESI-TOF) m/z: [M + H]+ calcld for C23H26NO5, 396.1805; found, 396.1801.

Analytical data of further synthesized compounds can be found in Supporting Information File 2.

Experimental procedure for the synthesis of compound 7

The mixture of tetronic acid 4a (0.37 g, 1 mmol) and hydrazine hydrate (0.1 g, 2 mmol) in EtOH (5 mL) was refluxed for 2 h. The resulting precipitate was filtered off and washed with EtOH (3 × 5 mL).

(3E,5E)-3-(1-Hydrazinylethylidene)-5-(3-oxo-2-phenethyl-2-azaspiro[4.5]decan-1-ylidene)furan-2,4(3H,5H)-dione (7). White powder; yield 71% (0.29 g); mp 199–201 °C; 1H NMR (300 MHz, DMSO-d6) δ 12.11 (br. s, 1H), 7.30–7.12 (m, 5H), 5.72 (s, 2H), 4.47 (t, J = 7.5 Hz, 2H), 2.68 (t, J = 7.7 Hz, 2H), 2.56–2.48 (m, 2H in DMSO), 2.46 (s, 3H), 2.15 (t, J = 12.9 Hz, 2H), 1.63–1.53 (m, 2H), 1.40–1.11 (m, 5H); 13C NMR (75 MHz, DMSO-d6) δ 179.8, 175.3, 164.8, 140.4, 138.4, 129.0, 128.4, 128.3, 126.3, 88.98, 43.7, 43.5, 39.7, 32.8, 32.3, 24.9, 22.0, 12.8; HRMS (ESI-TOF) m/z: [M + H]+ calcld for C23H28N3O4, 410.2074; found, 410.2092.

Experimental procedure for the synthesis of compound 9

The mixture of tetronic acid 4a (0.39 g, 1 mmol) and 3-chlorobenzylamine (0.16 g, 1.1 mmol) in EtOH (5 mL) was refluxed for 2 h. The resulting precipitate was filtered off and washed with EtOH (3 × 5 mL).

(3E,5E)-3-(1-((3-Chlorobenzyl)amino)ethylidene)-5-(3-oxo-2-phenethyl-2-azaspiro[4.5]decan-1-ylidene)furan-2,4(3H,5H)-dione (9). White powder; yield 65% (0.34 g); mp 158–160 °C. 1H NMR (300 MHz, DMSO-d6) δ 11.59 (s, 1H), 7.53–7.41 (m, 3H), 7.41–7.35 (m, 2H), 7.23–7.10 (m, 4H), 4.82 (d, J = 6.1 Hz, 2H), 4.42 (t, J = 7.6 Hz, 2H), 2.67 (t, J = 7.8 Hz, 2H), 2.57 (s, 3H), 2.54 (s, 2H), 2.16 (t, J = 12.9 Hz, 2H), 1.69–1.53 (m, 3H), 1.42–1.08 (m, 5H); 13C NMR (75 MHz, DMSO-d6) δ 175.7, 171.6, 139.4, 138.7, 138.7, 136.8, 136.6, 136.0, 134.0, 131.3, 129.4, 128.6, 128.4, 128.1, 127.9, 127.8, 126.7, 46.4, 44.3, 44.0, 33.3, 32.6, 25.2, 22.4, 14.8; HRMS (ESI-TOF) m/z: [M + H]+ calcld for C30H32ClN2O4, 519.2045; found, 519.2051.

Supporting Information

Supporting Information File 1: General information, copies of NMR spectra, X-ray crystallographic data and refinement details.
Format: PDF Size: 5.8 MB Download
Supporting Information File 2: Analytical data of all compounds 4, 7 and 9.
Format: PDF Size: 277.9 KB Download

Acknowledgements

Crystal structure determination was performed in the Department of Structural Studies of Zelinsky Institute of Organic Chemistry, Moscow.

Data Availability Statement

All data that supports the findings of this study is available in the published article and/or the supporting information to this article.

References

  1. May, O. E.; Moyer, A. J.; Wells, P. A.; Herrick, H. T. J. Am. Chem. Soc. 1931, 53, 774–782. doi:10.1021/ja01353a050
    Return to citation in text: [1]
  2. Megalla, S. E.; Nassar, A. Y.; Gohar, M. A. S. J. Basic Microbiol. 1987, 27, 29–33. doi:10.1002/jobm.3620270105
    Return to citation in text: [1]
  3. Barham, H. N.; Smits, B. L. Ind. Eng. Chem. 1936, 28, 567–570. doi:10.1021/ie50317a016
    Return to citation in text: [1]
  4. Bajpai, P.; Agrawala, P. K.; Vishwanathan, L. J. Gen. Microbiol. 1981, 127, 131–136. doi:10.1099/00221287-127-1-131
    Return to citation in text: [1]
  5. Dung, T. T. M.; Kim, S. C.; Yoo, B. C.; Sung, G.-H.; Yang, W. S.; Kim, H. G.; Park, J. G.; Rhee, M. H.; Park, K. W.; Yoon, K.; Lee, Y.; Hong, S.; Kim, J.-H.; Cho, J. Y. Int. Immunopharmacol. 2014, 20, 37–45. doi:10.1016/j.intimp.2014.02.019
    Return to citation in text: [1]
  6. Wang, K.; Liu, C.; Di, C.-J.; Ma, C.; Han, C.-G.; Yuan, M.-R.; Li, P.-F.; Li, L.; Liu, Y.-X. Asian Pac. J. Cancer Prev. 2014, 15, 291–297. doi:10.7314/apjcp.2014.15.1.291
    Return to citation in text: [1]
  7. Khan, A.; Park, T. J.; Ikram, M.; Ahmad, S.; Ahmad, R.; Jo, M. G.; Kim, M. O. Mol. Neurobiol. 2021, 58, 5127–5140. doi:10.1007/s12035-021-02460-4
    Return to citation in text: [1]
  8. Wei, X.; Luo, D.; Yan, Y.; Yu, H.; Sun, L.; Wang, C.; Song, F.; Ge, H.; Qian, H.; Li, X.; Tang, X.; Liu, P. Exp. Eye Res. 2019, 180, 174–183. doi:10.1016/j.exer.2018.12.020
    Return to citation in text: [1]
  9. Rajamanikyam, M.; Gade, S.; Vadlapudi, V.; Parvathaneni, S. P.; Koude, D.; Kumar Dommati, A.; Kumar Tiwari, A.; Misra, S.; Sripadi, P.; Amanchy, R.; Upadhyayula, S. M. Process Biochem. (Oxford, U. K.) 2017, 56, 45–56. doi:10.1016/j.procbio.2017.02.010
    Return to citation in text: [1]
  10. Karakaya, G.; Ercan, A.; Oncul, S.; Aytemir, M. D. Anti-Cancer Agents Med. Chem. 2018, 18, 2137–2148. doi:10.2174/1871520618666180402141714
    Return to citation in text: [1]
  11. Gonçalez, M. L.; Marcussi, D. G.; Calixto, G. M. F.; Corrêa, M. A.; Chorilli, M. BioMed Res. Int. 2015, 04591. doi:10.1155/2015/304591
    Return to citation in text: [1]
  12. Aytemir, M. D.; Çalış, Ü. Arch. Pharm. (Weinheim, Ger.) 2010, 343, 173–181. doi:10.1002/ardp.200900236
    Return to citation in text: [1]
  13. Da Costa, J. P.; Rodrigues, A. P. D.; Farias, L. H. S.; Frade, P. C. R.; Da Silva, B. J. M.; Do Nascimento, J. L. M.; Silva, E. O. Biomed. Pharmacother. 2018, 101, 100–106. doi:10.1016/j.biopha.2018.02.036
    Return to citation in text: [1]
  14. Khezri, K.; Saeedi, M.; Morteza-Semnani, K.; Akbari, J.; Hedayatizadeh-Omran, A. Artif. Cells, Nanomed., Biotechnol. 2021, 49, 38–47. doi:10.1080/21691401.2020.1865993
    Return to citation in text: [1]
  15. Yap, W. N.; Zaiden, N.; Xu, C. H.; Chen, A.; Ong, S.; Teo, V.; Yap, Y. L. Pigm. Cell Melanoma Res. 2010, 23, 688–692. doi:10.1111/j.1755-148x.2010.00740.x
    Return to citation in text: [1]
  16. Cabanes, J.; Chazarra, S.; Garcia-Carmona, F. J. Pharm. Pharmacol. 1994, 46, 982–985. doi:10.1111/j.2042-7158.1994.tb03253.x
    Return to citation in text: [1]
  17. Safaei, S.; Mohammadpoor-Baltork, I.; Khosropour, A. R.; Moghadam, M.; Tangestaninejad, S.; Mirkhani, V.; Khavasi, H. R. ACS Comb. Sci. 2013, 15, 141–146. doi:10.1021/co3001204
    Return to citation in text: [1]
  18. O'Malley, M. M.; Damkaci, F.; Kelly, T. R. Org. Lett. 2006, 8, 2651–2652. doi:10.1021/ol061002c
    Return to citation in text: [1]
  19. Norton, S. J.; Skinner, C. G.; Shive, W. J. Org. Chem. 1961, 26, 1495–1498. doi:10.1021/jo01064a044
    Return to citation in text: [1]
  20. Beyerman, H. C. Recl. Trav. Chim. Pays-Bas 1958, 77, 249–257. doi:10.1002/recl.19580770306
    Return to citation in text: [1]
  21. Teitei, T. Aust. J. Chem. 1983, 36, 2307–2315. doi:10.1071/ch9832307
    Return to citation in text: [1]
  22. Tu, X.-J.; Fan, W.; Hao, W.-J.; Jiang, B.; Tu, S.-J. ACS Comb. Sci. 2014, 16, 647–651. doi:10.1021/co500100c
    Return to citation in text: [1]
  23. Mascareñas, J. L.; Rumbo, A.; Castedo, L. J. Org. Chem. 1997, 62, 8620–8621. doi:10.1021/jo9716439
    Return to citation in text: [1]
  24. Barfoot, C. W.; Brown, P.; Dabbs, S.; Davies, D. T.; Hennessy, A. J.; Miles, T. J.; Pearson, N. D. Tetrahedron Lett. 2010, 51, 5038–5040. doi:10.1016/j.tetlet.2010.07.099
    Return to citation in text: [1]
  25. Storr, T.; Mitchell, D.; Buglyó, P.; Thompson, K. H.; Yuen, V. G.; McNeill, J. H.; Orvig, C. Bioconjugate Chem. 2003, 14, 212–221. doi:10.1021/bc025606m
    Return to citation in text: [1]
  26. Öztürk, G.; Erol, D. D.; Aytemir, M. D.; Uzbay, T. Eur. J. Med. Chem. 2002, 37, 829–834. doi:10.1016/s0223-5234(02)01390-9
    Return to citation in text: [1]
  27. Öztürk, G.; Erol, D. D.; Uzbay, T.; Aytemir, M. D. Farmaco 2001, 56, 251–256. doi:10.1016/s0014-827x(01)01083-7
    Return to citation in text: [1]
  28. Hare, L. E.; Lu, M. C.; Sullivan, P. T.; Counsell, R. E.; Weinhold, P. A. J. Med. Chem. 1974, 17, 1–5. doi:10.1021/jm00247a001
    Return to citation in text: [1]
  29. Molenda, J. J.; Basinger, M. A.; Hanusa, T. P.; Jones, M. M. J. Inorg. Biochem. 1994, 55, 131–146. doi:10.1016/0162-0134(94)85035-6
    Return to citation in text: [1]
  30. Thomas, A. F.; Marxer, A. Helv. Chim. Acta 1960, 43, 469–477. doi:10.1002/hlca.19600430202
    Return to citation in text: [1]
  31. Ichimoto, I.; Fujii, K.; Tatsumi, C. Agric. Biol. Chem. 1967, 31, 979–989. doi:10.1271/bbb1961.31.979
    Return to citation in text: [1]
  32. Komogortsev, A. N.; Lichitskii, B. V.; Melekhina, V. G. Org. Biomol. Chem. 2023, 21, 7224–7230. doi:10.1039/d3ob01136d
    Return to citation in text: [1]
  33. Komogortsev, A. N.; Lichitsky, B. V.; Tretyakov, A. D.; Dudinov, A. A.; Krayushkin, M. M. Chem. Heterocycl. Compd. 2019, 55, 818–822. doi:10.1007/s10593-019-02542-1
    Return to citation in text: [1] [2]
  34. Milyutin, C. V.; Galimova, R. D.; Komogortsev, A. N.; Lichitskii, B. V.; Melekhina, V. G.; Migulin, V. A.; Fakhrutdinov, A. N.; Minyaev, M. E. Org. Biomol. Chem. 2021, 19, 9975–9985. doi:10.1039/d1ob01871j
    Return to citation in text: [1] [2]
Other Beilstein-Institut Open Science Activities